Dr Reddy's Labs unveils Saxagliptin, Metformin Hydrochloride ER Tablets in US
Hyderabad: Dr. Reddy's Laboratories Ltd. has announced its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market.
According to WHO, Type 2 diabetes affects how your body uses sugar (glucose) for energy. It stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated. Over time, type 2 diabetes can cause serious damage to the body, especially nerves and blood vessels. Factors that contribute to developing type 2 diabetes include being overweight, not getting enough exercise, and genetics.
KOMBIGLYZE is a registered trademark of the AstraZeneca group of companies.
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd